#immunotherapy — Thursday, May 28, 2026 (2 items)
| 0 | 💬 0 |
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.
(nejm.org)
|
New England Journal of Medicine 2026-05-28 | #antibody #cancer #clinical trial #immunotherapy | |
| 0 | 💬 0 |
A high-throughput selection system for fast-acting covalent protein drugs.
(science.org)
|
Science 2026-05-28 | #immunotherapy #protein design #directed evolution #drug design |